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Background: The hypothesis that most cancers are of monoclonal origin is often accepted as a fact in the scientific
community. This dogma arose decades ago, primarily from the study of hematopoietic malignancies and sarcomas,
which originate as monoclonal tumors. The possible clonal origin of malignant mesothelioma (MM) has not been
investigated. Asbestos inhalation induces a chronic inflammatory response at sites of fiber deposition that may lead
to malignant transformation after 30-50 years latency. As many mesothelial cells are simultaneously exposed to
asbestos fibers and to asbestos-induced inflammation, it may be possible that more than one cell undergoes
malignant transformation during the process that gives rise to MM, and result in a polyclonal malignancy.
Methods and results: To investigate the clonality patterns of MM, we used the HUMARA (Human Androgen
Receptor) assay to examine 16 biopsies from 14 women MM patients. Out of 16 samples, one was non-informative
due to skewed Lyonization in its normal adjacent tissue. Fourteen out of the 15 informative samples revealed two
electrophoretically distinct methylated HUMARA alleles, the Corrected Allele Ratio (CR) calculated on the allele peak
areas indicating polyclonal origin MM.
Conclusions: Our results show that MM originate as polyclonal tumors and suggest that the carcinogenic “field
effect” of mineral fibers leads to several premalignant clones that give rise to these polyclonal malignancies.
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Malignant mesothelioma (MM) is an aggressive cancer
arising from the transformation of the mesothelial lining
of the pleura, peritoneum and pericardium. It is a lethal
cancer affecting approximately 3,200 individuals each
year in the US, most of them die within 1 year from
diagnosis [1]. MM incidence has remained stable in the
US since 2003, but it continues to increase worldwide,
due to exposure to asbestos fibers, which are widely used
for industrial purposes [1]. Occupational exposure ac-
counts for a male to female MM incidence ratio of 6-8
to 1, as males are much more often involved in the* Correspondence: mcarbone@cc.hawaii.edu
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article, unless otherwise stated.asbestos industrial trades [2]. Asbestos, erionite and
other mineral fibers are also naturally present in devel-
oping rural areas where they pose a major risk factor for
MM [3,4]. Asbestos inhalation induces a chronic inflam-
matory response at sites of fibers deposition that may
lead to malignant mesothelial cell transformation after a
latency of 30- to 50-years [5]. In addition to the environ-
mental and inflammatory components of MM etiology,
we have recently discovered that germline mutations of
the BAP1 gene cause a novel cancer syndrome charac-
terized by a very high incidence of MM, and other ma-
lignancies [6].
MMs show different histology. There are 3 main sub-
types: about 50% of MM show an epithelioid morph-
ology and they look like carcinomas, 10% have a spindle
cell morphology similar to sarcomas, and about 35% are
biphasic, composed of both epithelioid and spindle cells
in different proportions. In addition there are lesstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Clinical features and clonality pattern in 16
biopsies from 14 female MM patients
Sample ID Age Histology Staging Clonality
6 ND Biphasic NA Polyclonal
61 82 Epithelioid III Polyclonal
93 64 Epithelioid III Polyclonal
207A 74 Epithelioid III Polyclonal
207B Polyclonal
273 66 Biphasic III Polyclonal
524A 72 Epithelioid III Polyclonal
524B Monoclonal
851 58 Biphasic III Polyclonal
1250 65 Epithelioid III Polyclonal
1359 56 Epithelioid III Polyclonal
1419 25 Biphasic III Polyclonal
L-III-18 64 Epithelioid III Non-informative
R693 63 Epithelioid III Polyclonal
R908 69 Epithelioid I Polyclonal
W-III-6 66 Epithelioid II Polyclonal
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complicated by the presence of intra-tumoral pleomor-
phisms and phenotypic heterogeneity, raising the question
of whether MM results from genetic and epigenetic alter-
ations, which drive clonal tumor evolution into these dif-
ferent morphologies, or it arises from different subsets of
mesothelial cells that interact or cooperate to drive malig-
nant progression.
Multistep carcinogenesis is the currently accepted hy-
pothesis to explain genetic diversity in tumors [8-10].
This hypothesis is based on the notion that somatic mu-
tations are rare events that are unlikely to co-occur in
different single normal cells, and that the mutations
leading to the genetic diversification of the tumor archi-
tecture occur during the process of clonal expansion and
selection. A cancer is considered monoclonal when all cells
within the tumor can be traced back to a single progeni-
tor/initiator cell. Instead, a polyclonal malignancy derives
from the concomitant transformation of two or more dif-
ferent ancestor cells. Determining the clonal status of a
cancer can be quite challenging, because of the inherent
plasticity of the cancer genome that can acquire many
somatic mutations during malignant cell growth. Analysis
of the X chromosome inactivation pattern in female cancer
biopsies, by measuring the methylation status of the poly-
morphic human androgen receptor (HUMARA) locus, is
considered the most accurate method to assess clonality
[11]. During early female embryogenesis, one of the two X
chromosomes is randomly inactivated and the pattern of
X-chromosome inactivation is stably transmitted from par-
ent cell to the progeny (Lyonization) [12]. Therefore, the
presence of the same inactivated X chromosome in all can-
cer cells has been interpreted as an indication of mono-
clonality. Although the current dogma is that cancers
originate as monoclonal growths, some studies suggest that
some cancers may arise as polyclonal [13,14].
To the best of our knowledge, the clonal origin of MM
has never been investigated. However MMs are “as-
sumed” to be monoclonal as most tumors are usually as-
sumed to be. Here we tested the hypothesis that MMs
are monoclonal using the HUMARA assay on 16 MM
biopsies from 14 female patients. We found that human
MMs are polyclonal in origin.
Methods
Clinical specimens and study approval
Human MM biopsies were collected at the following insti-
tutions: Department of Cardiothoracic Surgery, New York
University, New York, NY; MedStar Washington Hospital
Center, Washington, DC; University of Wisconsin School
of Medicine and Public Health Department of Surgery,
Madison, WI, and at the Department of Surgery, Penn
Presbyterian Medical Center, Philadelphia, PA.All tissue collections were approved by the Institutional
Review Boards. Written and informed consent was ob-
tained from all patients included in the study according to
the guidelines set forth by the Institutional Review Board
and in agreement with the Helsinki Declaration of 1975,
as revised in 1983. Specimens were de-identified prior to
analysis. Tissues collected during surgical tumor resection
were immediately frozen and processed for laser microdis-
section, DNA extraction and immunohistochemistry.
Clinical features are included in Table 1. Laser microdis-
section and all following experimental procedures were
conducted at the University of Hawai‘i Cancer Center.
HUMARA assay
HUMARA assay (Figure 1) examines the methylation
status of the X chromosome at the HUMARA gene; this
is a highly polymorphic locus, which allows the distinc-
tion between the paternal and maternal alleles that carry
a different number of -CAG- repeats [15]. The assay is
based on digestion of tumor DNA with the methylation
sensitive HpaII restriction enzyme that can only digest
the unmethylated allele by recognizing the -CCGG- se-
quence within the HUMARA gene. After digestion, the
methylated, therefore ‘protected’ allele, is amplified by
PCR; the HUMARA -CAG- repeats are approximately
100 bp from the HpaII restriction site, allowing amplifi-
cation and detection of a portion of the methylated al-
lele, which remains intact after digestion [15]. PCR
products are then analyzed by electrophoresis to deter-
mine allele number and quantify allele intensity. Using
this assay, a monoclonal tumor population expanded
Figure 1 Schematic diagram of the HUMARA assay. Maternal and paternal X chromosomes carry different numbers of CAG repeats at the
Humara locus. HpaII methylation sensitive sites are located at the polyorphic CAG region. During embriogenesis, random X chromosome inactivation
occurs in female individuals, resulting in methylation of either the paternal or maternal X chromosome in different cells. Therefore, a monoclonal cell
population, derived from the division of a single ancestor cell, shares the same inactivated X chromosome, whereas a polyclonal population, derived
from more than one ancestor cell, may contain cells with inactive maternal and paternal X chromosomes. HpaII digestion removes the unmethylated
alleles, allowing amplification of the methylated HUMARA locus. Electrophoresis of the PCR products will indicate monoclonal or polyclonal cell
populations, as a single band or two bands of different size, respectively. HpaII: denotes the methylation sensitive endonuclease sites; arrows: indicate
primer annealing regions; cross bars: indicate the methylated chromosome.
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chromosome in all cells, will result in a single PCR prod-
uct, while two PCR products of different molecular size
will indicate a polyclonal tumor cell population, where
the tumor cells are derived from more than one cell of
origin (Figure 1). The extent of allele representation in a
tissue is then determined by comparing the amount of
PCR products obtained from the two digested alleles to
mock-digested samples. This compensates for the pref-
erential amplification of the smaller allele. The allele ra-
tio found in the tumor sample is then divided by the
allele ratio measured in DNA from nearby normal
tissue, to correct for possible skewed Lyonization, a
phenomenon of unbalanced, non-random X chromo-
some inactivation that occurs in about 10% of a healthy
female population [16].Laser tissue microdissection and DNA extraction
HUMARA clonality assessment [11,15,17] was con-
ducted on stage I to III MM biopsies (Table 1). A limita-
tion of this test is that, it can be used only on female
specimens. Although MM is rare in women, we were
able to collect and study clonality in 16 MM biopsies
from 14 women that were treated by some of the co-
authors. In 2 out of 14 cases, two distinct nodules from
the same pleura were available for comparison. Tumors
and adjacent normal tissues were dissected by Laser
Capture Microdissection, using MMI CellCut Plus
(Molecular Machines & Industries, MI, USA). Hematoxylin
and Eosin (H&E) staining was used to help identify tissue
purity. Microdissection was performed on serial sections
stained with Hematoxilin (i.e., cut next to the one stained
with H/E) on tumor areas containing less than 5% of
Figure 2 HUMARA assay quality controls. HUMARA-PCR was
performed on HpaII-digested (H+) and mock-digested DNA (H-) from
a healthy male and analyzed by capillary gel electrophoresis, using
the 3100 Genome Analyzer. Presence of a single PCR peak indicated
complete DNA digestion by HpaII enzyme (A). Healthy female DNA
sample (L-IV-II, upper panel) and DNA from a human monoclonal
melanoma cell line (#1290, female, lower panel) were subjected to
HUMARA assay. After HpaII digestion, gel (inserts) and capillary
electrophoresis successfully detected a polyclonal pattern and a
monoclonal pattern, respectively (B).
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normal tissue (control) (Additional file 1: Figure S1).
HUMARA assay was performed on DNA extracted
from microdissected tissues. DNA was extracted from
microdissected tissue using the QiAamp DNA Micro Kit
DNA Extraction Protocol (Qiagen). DNAs were then
digested with HpaII enzyme as previously described [17]:
briefly, 100 ng of either tumor or normal DNA were
digested with 10 U Hpa II restriction enzyme (New
England Biolabs, Ipswich, MA, USA) at 37°C overnight
in a 20 μl reaction volume. Separate aliquots of DNA
were subjected to mock digestion without the enzyme.
After incubation, the restriction enzyme was inactivated
at 80°C for 20 min. HpaII-digested or mock-digested
DNA was then subjected to PCR reaction, using the fol-
lowing primers: 5 FAM-labeled forward primer, 5’ACC
GAG GAG CTT TCC AGA AT3’; reverse primer,
5’TGG GGA GAA CCA TCC TCA C3’. Thermal cyc-
ling conditions included the following steps: denatur-
ation at 95°C for 10 minutes; 30 cycles at 95°C for
30 seconds, 55°C for 30 seconds, and 72°C for 30 sec-
onds; and a final extension at 72°C for 10 minutes.
Products of PCR amplification were analyzed by gel
and capillary electrophoresis. Gel electrophoresis was
performed on 3% agarose gel containing ethidium
bromide (10ug/ml), and resolved DNA bands were vi-
sualized on a UV transilluminator (Biorad). For capil-
lary electrophoresis, PCR products were mixed with
95% formamide and loading buffer (5% blue dextran,
25 mM EDTA) containing Rox-500. The mixture was
then loaded on a 5% Long Ranger–6 M urea gel in TBE
buffer. Electrophoresis was performed at 200 W for
2.25 hours, and the data were analyzed by an on a ABI
3100 Genetic Analyzer (Applied Biosystems, Foster City,
CA) and quantified by Genescan 3.1 software (Applied
Biosystems). Mock-digested samples were used to monitor
possible false positive results and to correct allele ratios.
All samples were analyzed in triplicate. The ratio SD/
mean CR was <2% for all replicates indicating that results
were 100% reproducible and reliable.
Data analysis
For each sample, the allele intensities were measured as
the peak areas of both alleles, which are proportional to
the molar amount of DNA. The allele ratios (AR) were
first calculated by dividing the ratio (RU = A1U/A2U) of
the non-HpaII digested sample by the ratio (RD = A1D/
A2D). The AR calculation (AR = RU/RD) corrects for any
preferential amplification of one allele that might occur
if the alleles are different in length. The clonality ratio
(CR) is then calculated by dividing the AR of the tumor
DNA by the AR calculated for the normal tissue (CR =
ART÷ARN). This final calculation corrects for a potential
skewed Lyonization [18,19]. A CR ≥3.0 or ≤0.33,representing a preferential loss of intensity in the
digested sample of one of the two alleles present in the
tumor sample, was scored as a monoclonal pattern
[18,19].
The Wald method was used to calculate the confi-
dence interval for the observed proportion of polyclonal-
ity in our sample population.
Results and discussion
To address whether MM have monoclonal or polyclonal
origin, we performed the HUMARA assay, as described
in Methods and Figure 1 [11,15,17]. We first performed
the HUMARA assay on control samples (Figure 2). A
healthy male DNA sample (monoallelic, bearing a single
unmethylated X chromosome) was digested as described
in the material and methods and analyzed by agarose gel
and capillary electrophoresis. Disappearance of the PCR
band/peak indicated complete allele digestion, thus
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plete HpaII digestion (Figure 2A). A healthy female
DNA sample (L-IV-II, biallelic) and a known monoclo-
nal melanoma cell line (#1290, female) were used as
additional controls. As shown in Figure 2B, gel and ca-
pillary electrophoresis successfully detected a polyclonal
and a monoclonal pattern, respectively.
Next, we established the sensitivity of the HUMARA
assay in the detection of under-represented alleles by both
gel and capillary electrophoresis (Figure 3). Mono-allelic
(HpaII-digested) and bi-allelic (non-digested) DNA from
the 1290 melanoma monoclonal cell line were mixed in
different proportions. PCR products were resolved by
electrophoresis on 3% agarose gel and visualized under
UV light in the presence of ethidium bromide (Figure 3A),
or by capillary electrophoresis using a Genotypic Bioanaly-
zer (Applied Biosystems) (Figure 3B). Linear regression ofFigure 3 Sensitivity of the HUMARA assay by gel and capillary electroph
minor alleles, different amounts of HpaII-digested (mono-allelic) and non-dige
rations and subjected to PCR for detection of HUMARA locus. PCR products w
bromide and detected under UV light (A) or using the Applied Biosystems 31
50, 25, 12.5, 6.25 and 0 indicate the percentage of bi-allelic DNA in the PCR re
shows comparison between input and detected allelic/biallelic ratios as calcu
detectable when present at a fraction greater than or equal to 1/8 (12.5% of tinput vs detected allele ratios revealed a robust correlation
(R2 > 0.98), with the less frequent allele detectable when
present at a fraction greater than or equal to 1/8 (12.5% of
the input copies) (Figure 3C).
HUMARA clonality assessment was conducted on 16,
stage I to III, frozen biopsies from 14 cases of female
MMs (Table 1). In 2 out of 14 sporadic cases, two dis-
tinct nodules from the same pleura were available for
analysis, giving a total of 16 specimens. Samples were
classified as non-informative when a single band or peak
was detected in the nearby normal tissue after digestion
with the HpaII enzyme, indicating the presence of
skewed Lyonization. Out of the 16 biopsies tested, 15
were informative. Sample L-III-18, a case of familial
MM, was non-informative as PCR amplification of both
mock- and HpaII-digested DNA produced a single band,
suggesting that the lengths of the paternal and maternaloresis. To establish the sensitivity of the HUMARA assay for detection of
sted (representing bi-allelic DNA) #1290 DNA were mixed in different
ere resolved on a 3% agarose gel containing 0.5 ug/ml ethidium
00 Genetic Analyzer (B). CTR denotes the no template control. 100, 75,
action (A). Linear regression analysis calculated with Prism 6 software,
lated using Genescan software. (R2 > 0.98). The minor allele was reliably
he input copies) (C).
Figure 4 X chromosome inactivation analysis by HUMARA assay shows a prevalent polyclonal pattern of Malignant Mesotheliomas.
Gel electrophoresis (A). PCR products from mock digested (H-) and HpaII-digested (H+) DNA samples were separated on a 3% agarose gel and
visualized under UV light, using ethidium bromide. Capillary-Electrophoresis (B, C). HUMARA PCR assay was performed using a 5FAM-labeled
forward primer, and quantified by the Applied Biosystems 3100 Genetic Analyzer. Two major peaks denote the two allelic HUMARA loci
PCR-amplified in HpaII-digested (H+) and mock-digested samples (H-). The allele intensities were measured as peak area of both alleles, which is
proportional to the molar amount of DNA. Peak areas were calculated for each allele using Genescan software, as described in the Material and
Methods. A CR ≥3.0 or ≤0.33, representing a preferential loss of intensity in the digested sample of one of the two alleles present in the tumor
sample, was scored as a monoclonal pattern.
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formative biopsies, 14/15 PCR products (93.3%) dis-
played two distinct bands and peaks. 4 representative
samples are shown in Figure 4A and B. Corrected Allele
Ratio (CR) calculated on the allele peak areas by Geno-
typic Bioanalyzer was within the values of 0.33 and 3.0,
indicating polyclonality of all 14 samples (Figure 4B and
Table 1). The observed proportion of polyclonality was
93.33% (14/15), with a 95% confidence interval of
[68.16% - 100%], indicating that the proportion of poly-
clonality in our sample population did not differ signifi-
cantly from 100%. Therefore our results reveal with
confidence that MM are polyclonal at origin. Case #524
showed a quite distinct pattern, as one nodule (#524B)
revealed a monoclonal pattern (CR = 0.19), while the
other (#524A) was polyclonal (CR = 0.36; Figure 4C).
This finding suggested that a particular clone maydominate a certain area within a largely polyclonal tumor,
composed of clones derived from different cells of origin.
Of note, both sporadic MMs, that usually develop on a
background of asbestos exposure, and familial MMs that
develop on a background of germline BAP1 mutations
were found to be polyclonal. All these MM samples were
from women, as the HUMARA assay used here to assess
clonality, cannot be used on specimen from men. MMs in
women are rare and have a slightly better prognosis than
MM in man [20], a finding that some studies suggested
might be related to the expression of the estrogen receptor
beta [21]. However, there is no evidence in the literature
supporting the hypothesis that women and man MM have
a different pathogenesis, thus it seems unlikely that poly-
clonality of MM is influenced by gender-associated fac-
tors. It should also be noted that all these MMs were
either of the epithelial or of the biphasic type (Table 1),
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toid MMs that account for about 10% of all MMs, because
these specimens were not available, as they are rare and as
these patients are not candidates for surgical resection [2].
Thus, clonality of sarcomatoid MMs remains to be tested.
X-chromosome inactivation based assays may detect a
seemingly monoclonal tumor when transformation oc-
curs in multiple cells having the same inactivated X
chromosome. Although possible, this is a rare event,
mainly dependent on the X-inactivation patch size dur-
ing early developmental Lyonization. This event leads
few of the progeny of a single embryonic stem cell to be
grouped together in the adult, forming patches. This
phenomenon has been described in breast tissues, which
display a rather large patch size [12]. Alternatively, a true
monoclonal nodule may result from the clonal outgrow
of a particular cell with proliferative advantage, as previ-
ously described in breast and prostate cancer, e.g. due to
acquisition of LOH of the X-linked tumor suppressor
FOXP3 [22,23]. The notion that tumors derive from a
single cell through the expansion and evolution of sev-
eral clones has survived mostly unchallenged until the
present time. Accordingly, much effort has been placed
in using genomic approaches to dissect the clonal rela-
tionships present within single tumors [8]. Despite the
advances of the molecular genetic analyses, to date, the
HUMARA assay is unique in its capability of detecting
the actual origin of a cell population. Our data indicate
that MMs may arise as polyclonal tumors due to concur-
rent transformation of multiple mesothelial cells (Figure 5).
Recent studies conducted in some breast and colon car-
cinomas showed that they were polyclonal [13,14,24,25],
supporting the novel concept that not all tumors are
monoclonal at origin. Also, a recent study using mouseFigure 5 MMs originate as polyclonal tumors. Asbestos fibers travel thr
reach the pleura, exposing many mesothelial cells. The carcinogenic “field e
rise to these polyclonal malignancies.chimeras, provides evidences suggesting that intestinal tu-
mors may be polyclonal and that inter-clonal interactions
are necessary for tumor development [13]. Our results
that MMs are polyclonal indicate that MMs are likely to
be clonally complex at the outset. The polyclonal origin of
MM may account for the very high degree of intra-
tumoral heterogeneity found in these malignancies, and
also contribute to the emergence of drug-resistant sub-
populations. Therefore, our finding suggest that solely
tracking the clonal evolution of a predominant clone may
not be sufficient to successfully target MM, providing a
possible rationale to the peculiar resistance of MM to
current therapies.
Conclusions
Our data indicate that MM arise as polyclonal tumors, a
finding that has both pathogenesis and clinical implica-
tions. For example, MM patients whose tumors are re-
moved at Stage Ia, most often experience recurrence
after surgery in spite of apparent successful MM eradica-
tion [20].
Our data suggest that, in contrast to current dogma,
recurrence may represent novel malignancies, occurring
because of the carcinogenic “field effect” of asbestos, its
related chronic inflammation, and/or because of ubiqui-
tous genetic predisposition in patients carrying germline
BAP1 mutations. Therefore, MM may arise from a large
pool of independent and mostly covert cancers, as ob-
served in some other malignancies [26]. Accordingly, the
multiple minuscule pleural nodules that are characteris-
tically found on the pleura of early-stage MM patients
are likely pre-malignant lesions or early tumors rather
than early local metastases. Our findings underscore the
need to attack simultaneously several different molecularough the airways to the lungs, and, from there, via the lymphatics,
ffect” of mineral fibers leads to several premalignant clones that give
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as each clone may carry its own distinct set of molecular
alterations.
Additional file
Additional file 1: Figure S1. Laser capture microdissection of MM. H&E
of a representative MM tumor section is shown before (A) and after (B)
tumor tissue collection by laser capture microdissection (200x magnification).
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